Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AdheriumASX:ADR Debt-to-EBITDA is -0.12 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Adherium ranks worse than 213219.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Adherium's Debt-to-EBITDA or its related term are showing as below:
ASX:ADR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.25 Med: -0.01 Max: -0.01
Current: -0.11
During the past 10 years, the highest Debt-to-EBITDA Ratio of Adherium was -0.01. The lowest was -0.25. And the median was -0.01.
ASX:ADR's Debt-to-EBITDA is ranked worse than 100% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs ASX:ADR: -0.11
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Adherium Debt-to-EBITDA Related Terms
Adherium Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Adherium's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ADR vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Adherium's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adherium Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Adherium's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adherium's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Adherium (ASX:ADR) has a Debt-to-EBITDA of -0.12 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adherium. According to the industry distribution chart, Adherium ranks #999999 out of 469 companies in the Medical Devices & Instruments industry.
Is Adherium's Debt-to-EBITDA too high?
Adherium's current Debt-to-EBITDA is -0.12. Based on the distribution chart, Adherium ranks #999999 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Adherium's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Adherium ranks #999999 out of 469 companies for Debt-to-EBITDA. This places Adherium in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adherium. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adherium's current Debt-to-EBITDA is -0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adherium stock overvalued right now?
Based on GuruFocus' analysis, Adherium (ASX:ADR) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.34, compared to a current price of A$0.11 — trading 67.6% below its estimated fair value. The current Debt-to-EBITDA is -0.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Adherium (ASX:ADR), the current Debt-to-EBITDA is -0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address sub-optimal medication use and improve health outcomes in chronic disease. It is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. Its geographically segments include New Zealand and Australia, Europe, North America, and Asia. The majority of its revenue comes from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ADR has been successfully added to your 
